Last reviewed · How we verify
NCT04838808: R2MI
Rivaroxaban in Type 2 Myocardial Infarctions
Phase 2, PHASE3 trial testing Rivaroxaban 2.5 MG [Xarelto] in Type II Myocardial Infarction in 8 participants. Completed in 3 January 2023.
12 May 2022
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 5 April 2021 |
| Primary completion | 12 May 2022 |
| Estimated completion | 3 January 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Rivaroxaban 2.5 MG [Xarelto] — full drug profile →
- Placebo
Conditions studied
- Type II Myocardial Infarction — all drugs for Type II Myocardial Infarction →
Sponsor
University of Alberta
Who can join
45 and older, any sex, with Type II Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.
Al Said S, Kaier K, Sumaya W, Alsaid D, et al · · 2024 · cited 7× · PMID 38264795 · DOI 10.1002/14651858.cd014678.pub2 -
Anticoagulation in type 2 myocardial infarctions: Lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial.
Gouda P, Kay R, Gupta A, Yuen T, et al · · 2023 · cited 2× · PMID 37180843 · DOI 10.1016/j.conctc.2023.101143
Verify or expand the search:
- PubMed search for NCT04838808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban 2.5 MG [Xarelto]
Trials testing the same drug.
- NCT05077683 — Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APER · Phase 3 · completed
- NCT04753372 — Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk · completed
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04838808 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 27 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04838808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing